JNJ-10198409

JNJ-10198409 is a potent Platelet-Derived Growth Factor receptor tyrosine kinase (PDGF-RTK) inhibitor that functions through its interaction with the ATP binding site. It is reported to exhibit antiangiogenetic and tumor antiproliferative properties.

Zhang, L., Ma, J., Shen, T., Wang, S., Ma, C., Liu, Y.,... & Zhu, D. (2012). Platelet-derived growth factor (PDGF) induces pulmonary vascular remodeling through 15-LO/15-HETE pathway under hypoxic condition. Cellular signalling, 24(10), 1931-1939.
Battegay, E. J., Rupp, J., Iruela-Arispe, L., Sage, E. H., & Pech, M. (1994). PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. The Journal of cell biology, 125(4), 917-928.
Ho, C. Y., Ludovici, D. W., Maharoof, U. S., Mei, J., Sechler, J. L., Tuman, R. W.,... & Li, J. (2005). (6, 7-Dimethoxy-2, 4-dihydroindeno [1, 2-c] pyrazol-3-yl) phenylamines: Platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. Journal of medicinal chemistry, 48(26), 8163-8173.

Small volumes of JNJ-10198409 biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS696390 is a biochemical targeting JNJ-10198409.